Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (1-10 of 237) with videos related to

Pageof 24
Sort By:
Seminars in Oncology|March 13, 2016
Precision oncology: a strategy we were not ready to deployTito Fojo
JAMA Network Open|July 28, 2023
Journeys to Failure that Litter the Path to Developing New Cancer TherapeuticsTito Fojo
The New England Journal of Medicine|July 10, 2024
Sotorasib in KRAS-Mutated Colorectal CancerTito Fojo
Seminars in Oncology|March 13, 2024
Seminars in oncology 50th anniversaryTito Fojo
The Oncologist|April 2, 2008
Commentary: Novel therapies for cancer: why dirty might be betterTito Fojo
Cancer Journal (Sudbury, Mass.)|October 15, 2009
From the guest editor: monitoring of therapeutic response to cancer treatmentTito Fojo
Journal of the National Cancer Institute|October 5, 2006
Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents?Tito Fojo
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 14, 2007
Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAsTito Fojo
Seminars in Oncology|January 8, 2017
The high cost of ignorance in oncologyTito Fojo
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 27, 2002
p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53Tito Fojo
Pageof 24

Showing results (1-10 of 237) with videos related to

Sort By:
Pageof 24
Seminars in Oncology|March 13, 2016
Precision oncology: a strategy we were not ready to deployTito Fojo
JAMA Network Open|July 28, 2023
Journeys to Failure that Litter the Path to Developing New Cancer TherapeuticsTito Fojo
The New England Journal of Medicine|July 10, 2024
Sotorasib in KRAS-Mutated Colorectal CancerTito Fojo
Seminars in Oncology|March 13, 2024
Seminars in oncology 50th anniversaryTito Fojo
The Oncologist|April 2, 2008
Commentary: Novel therapies for cancer: why dirty might be betterTito Fojo
Cancer Journal (Sudbury, Mass.)|October 15, 2009
From the guest editor: monitoring of therapeutic response to cancer treatmentTito Fojo
Journal of the National Cancer Institute|October 5, 2006
Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents?Tito Fojo
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 14, 2007
Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAsTito Fojo
Seminars in Oncology|January 8, 2017
The high cost of ignorance in oncologyTito Fojo
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 27, 2002
p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53Tito Fojo
Pageof 24